WAVE LIFE SCIENCES LTD. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 3.43M shares, a 344.94% increase from fiscal 2024.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 770.64K shares, a 379.93% increase from fiscal 2023.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 160.57K shares, a 78.41% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 90.00K shares, a 73.22% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 3.43M shares 10-K · filed 2026-02-26 | |
| 2024-12-31 | 770.64K shares 10-K · filed 2025-03-04 | |
| 2023-12-31 | 160.57K shares 10-K · filed 2024-03-06 | |
| 2022-12-31 | 90.00K shares 10-K · filed 2023-03-23 | |
| 2021-12-31 | 51.96K shares 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |